The present invention relates to novel imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof, the synthesis thereof, and medicinal and/or pharmaceutical composition comprising these compounds thereof and synthesis thereof, and for use as a medicament, for use in the treatment of different diseases, advantageously of cancer.
The subject compounds are advantageously for use in the treatment of solid malignancies, advantageously breast, lung, melanoma, gliomas, and myeloproliferative and myelodysplastic neoplasms, colon cancer, acute myelogenous/myeloid leukemias by the differentiation and subsequent apoptosis of pre-matured myeloid leukemic cells or myeloid-derived suppressor cells and/or by direct effect on solid tumors.
Our invention relates to novel bicyclic imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives
wherein in general formula (V)
R1 represents hydrogen; branched or unbranched C1-C8-alkyl, aralkyl or aryl group advantageously optionally substituted phenyl or benzyl group; especially advantageously optionally substituted with 1; 2; 3; or 4 electron-withdrawing or electron-donating groups in ortho- metha and/or para positions;
furthermore represents heteroaryl groups and heterocycles in saturated or unsaturated forms containing O, N and/or S atoms; advantageously three-, four-, five-, six- and seven membered heterocyclic ring(s);
R2 represents hydrogen and branched or un-branched C1-C8-alkyl group;
R3 represents aliphatic branched or unbranched C1-C8-alkyl, advantageously tert-butyl, cyclopentyl, cyclohexyl group; aralkyl or aryl group advantageously optionally substituted phenyl or benzyl group; especially advantageously optionally substituted with 1; 2; 3; or 4 electron-withdrawing or electron-donating groups in ortho- metha and/or para positions;
furthermore represents heteroaryl groups and heterocycles in saturated or unsaturated forms containing O, N and/or S atoms, advantageously three-, four-, five-, six- and seven membered heterocyclic ring(s);
R4 represents aliphatic branched or unbranched C1-C8-alkyl, advantageously methyl, n-pentyl, 1,1,3,3-tetramethylbutyl, tert-butyl group; CH2R′ group wherein R′ represents hydrogen, branched or unbranched C1-C8 alkyl group; CO(OR″) group, wherein R″ represents branched or unbranched C1-C8 alkyl, aralkyl or aryl group advantageously optionally substituted phenyl or benzyl group, especially advantageously optionally substituted with 1; 2; 3; or 4 electron-withdrawing or electron-donating groups in ortho- metha and/or para positions;
furthermore represents heteroaryl groups and heterocycles in saturated or unsaturated forms containing O, N and/or S atoms, advantageously three-, four-, five-, six- and seven membered heterocyclic ring(s); C(O)R′ group, wherein R′ represents heteroaryl group;
X represents O- or S-atom,
advantageously X represents O atom where the general formula is (IV) and
advantagously X represents S atom where the general formula is (IV′);
wherein R1 furthermore represents especially advantageously a 4-fluoro-, 4-N-dimethylamino-, 2,4-difluoro-, 4-aminophenyl, 4-SMe, 4-OH substituted phenyl group; unsubstituted phenyl group; furthermore represents advantageously O, N or N-heterocycles, especially advantageously isoxazole and 3-pyridyl group;
wherein R2 represents advantageously hydrogen;
wherein R3 represents an aliphatic C1-C8-alkyl group, advantageously branched alkyl chain, especially advantageously tert-butyl, 1,1,3,3-tetramethylbutyl and/or alicyclic cyclohexyl group;
wherein R4 represents an aliphatic C1-C8-alkyl group, advantageously branched alkyl chain especially advantageously tert-butyl, 1,1,3,3-tetramethylbutyl and cyclohexyl group.
The subject matter of the invention furthermore relates advantageously to novel bicyclic imidazo[1,2-b]pyrazole carboxamide derivatives of general formula (V) advantageously of general formula (IV) or (IV′) as listed detailed as follows
The subject matter of the invention furthermore relates to medicinal and/or pharmaceutical compositions comprising the novel bicyclic imidazo[1,2-b]pyrazole carboxamide derivatives disclosed by general formula (V) advantageously of general formula (IV) or (IV′) and further advantageously named and listed specifically as above, and/or pharmaceutically acceptable salts thereof as active agent, which compositions are containing inert, pharmaceutically acceptable, solid or liquid carriers and/or excipients and furthermore relates to the process of formulating the composition comprising the compounds according to the invention.
The subject matter of the invention furthermore relates to
medicinal and/or pharmaceutical compositions, comprising at least one of the subject compounds advantageously solid composition, especially advantageously tablet, inhalation powder or capsule, advantageously semi-solid composition, especially advantageously suppository, or advantageously liquid composition especially advantageously solution for injection.
The subject matter of the invention furthermore relates to a novel process for the preparation of novel bicyclic imidazo[1,2-b]pyrazole carboxamide derivatives described by general formula (V) according to the invention and advantageously named specifically as above, carboxamides advantageously described by general formula (IV) where X represent an O atom, and carbothioamides described by general formula (IV′) where X represent an S atom and pharmaceutically acceptable salts thereof by reacting
a precursor aminopyrazole of general formula (I) where X represents an O atom or of general formula (I′), where X represents an S atom is synthesized from cyanoacetic acid derivative in a three steps manner.
According to the required substitution pattern, arbitrary combinations could be achieved.
The compounds according to the invention are prepared by three component protocol in which aminopyrazoles (I) or (I′) are conducted with the most diverse aldehydes (II) and isonitriles (III), which are commercially available from companies such as Sigma, Alfa Aesar or Fluorochem in the presence of perchloric acid (method A) or trifluoroacetic acid (method B) to form compounds of the general formula (V).
R1 to R4 and X here represent groups of the general formula (V).
The reactions are advantageously accomplished in acetonitril or THF (method A) besides EtOH/water 1:1 (method B) under mild conditions.
Due to the optimized conditions, most of the compounds of general formula (IV) were isolated by simple filtration.
The compounds of the general formula (V) can be converted into their pharmaceutically acceptable salts in a well-known manner to those skilled in the art with physiologically tolerated acids, advantageously hydrochloric acid, acetic acid, oxalic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid
To a suspension of pyrazole of general formulas (I) or (I′) (0.50 mmol) in MeCN or THF (0.5 mL) aldehyde of general formula (II) (0.55 mmol), HClO4 (20 mol %), and isocyanide of general formula (III) (0.55 mmol) were added and stirred at room temperature for 6 h. Then the crude mixture was purified by filtration followed by washing with cold MeCN or by column chromatography on silica gel (eluent: hexane/EtOAc or chloroform/methanol gradient) to afford pure products of general formulas (IV) or (IV′).
To a suspension of pyrazole of general formulas (I) or (I′) (0.50 mmol) in EtOH/water mixture (1:1, 1 mL) aldehyde of general formula (II) (0.55 mmol), TFA (20 mol %), and isocyanide of general formula (III) (0.55 mmol) were added and stirred at room temperature for 15 minutes.
Then the desired compound of general formulas (IV) or (IV′) was isolated by simple filtration followed by washing with water, then with EtOH.
The subject matter of the invention is furthermore the novel bicyclic imidazo[1,2-b]pyrazole carboxamide derivatives and pharmaceutically acceptable salt thereof according to the invention for use as a medicament for use in the treatment of different diseases, advantageously for treatment of cancer as anticancer agent, as first indication as active ingredient.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are advantageously for use in the treatment of solid malignancies, advantageously breast, lung, melanoma, gliomas, and myeloproliferative and myelodysplastic neoplasms, acute myelogenous/myeloid leukemias by the differentiation and subsequent apoptosis of pre-matured myeloid leukemic cells or myeloid-derived suppressor cells.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives according and pharmaceutically acceptable salts thereof to the invention are advantageously for use in the treatment of tumor by eradication of tumor through the differentiation of immature myeloid cells, monocytic and granulocytic myeloid-derived suppressor cells (MDSCs).
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are advantageously for use in the treatment of tumor by altering cancer cell metabolism as anti-cancer agent, because MDSCs promote tumor growth by several mechanisms including their inherent immunosuppressive activity, promotion of neoangiogenesis, mediation of epithelial-mesenchymal transition.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the treatment cancer The pro-tumoral functions of tumor-associated macrophages (TAMs) and MDSCs are further enhanced by their cross-talk offering a myriad of potential anti-cancer therapeutic targets.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the treatment for eliminating immature leukemia cells in leukemia, or diminishing tumor-promoting cells in solid tumor microenvironment as anti-cancer agent.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the treatment of solid tumor as anti cancer agent by restoration of T-cell immunity, since MDSCs represent immature myeloid cells with inherent immunosuppressive activity differentiation of MDSCs into mature myeloid cells
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the direct treatment of cells derived from leukemic, as cytotoxic agents.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the direct treatment of solid tumor cells as cytotoxic agents.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are furthermore advantageously for use in the treatment of cancer cells as anti cancer agent, by inducing differentiation of promyelocytic cells, differentiation induction of various solid cancer cells resulting in apoptosis and cell death by initiating a differentiation followed by subsequent apoptosis of cancer cells.
The novel bicyclic imidazo[1,2-b] pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof according to the invention are advantageously for use in the treatment of sepsis by differentiating MDSC.
The specification of the history, state of the art, concerning the novel imidazo-pyrazole carboxamide derivatives according to the invention, described by general formulas (V), (IV) and (IV′) according to the invention and advantageously named specifically as listed above and pharmaceutically acceptable salts thereof and concerning the medicines suitable for treatment of different diseases and comprising at least one of the subject compounds.
The prior art and patents referred and cited in the present specification hereinafter are all part of the state of the art.
The incorporation of the aminopyrazole scaffold into condensed heterocycles has emerged as a powerful strategy for novel anticancer drug development. Numerous pyrazolo[1,5-a]pyrimidines (Hanan et al. 2012; Dwyer et al. 2011; Labroli et al. 2011; Ren et al. 2012; Kosugi et al. 2012; Shaaban et al. 2011), pyrazolo[3,4-d]pyrimidines (Radi et al. 2011a; Dinér et al. 2012; Le Brazidec et al. 2012; Wang et al. 2012; Staben et al. 2010; Soth et al. 2011; Radi et al. 2011b; Yang et al. 2012), pyrazolo[1,5-a][1,3,5]triazines (Popowycz et al. 2009; Nie et al. 2008), pyrazolo[5,1-c][1,2,4]triazoles (Bondock et al. 2012; Hu et al. 2011), and other aminopyrazole-fused bicycles (Bindi et al. 2010; Lukasik et al. 2012; El-borai et al. 2012; Yu et al. 2010; Kim et al. 2011; Raffa et al. 2015; Li et al. 2014) display remarkable cancer-related enzyme inhibitory activities. Despite several synthetic routes are available for the construction of imidazo[1,2-b]pyrazole scaffold, only a limited number of reports focused on their antitumor potential (Sondhi et al. 2002; Terada et al. 1993; Frey et al. 2013; Elleder et al. 2009; Murlykin et al. 2017). In terms of anticancer activity, 3-aminoimidazo[1,2-b]pyrazole-7-carbonitriles 1 were shown to inhibit SYK with IC50 in sub-micromolar range (Zhang et al. 2010), while C7-ethyl ester analogues 2 acted as potent topoisomerase IIα catalytic inhibitors (Baviskar et al. 2011). Imidazo[1,2-b]pyrazole-7-carboxamides 3 were identified as Bruton's tyrosine kinase (BTK) inhibitors (Guo et al. 2014; Wang et al. 2017) and a series of C-7 aminomethylated derivatives 4 was synthesized and showed considerable antitumor activity against five human (A549, Hs683, MCF-7, SKMEL28, U373) and a murine (B16F10) cancer cell types (Grosse et al. 2014).
For a construction of an imidazo[1,2-b] based heterocyclic system, the Groebke-Blackburn-Bienaymé three-component reaction could be used, but substrate specific optimization and strategy is required all the time (GBB-3CR; conventional method: assembly of aldehyde, 2-amino-N-heterocycles and isocyanides in the presence of HClO4 catalyst in MeOH; Demjén et al., 2014; Shaaban et al. 2016; Liu 2015).
Myeloproliferative neoplasms (MPNs) are diseases of the bone marrow where an excess of cells are produced. These can evolve to myelodysplastic syndromes or myeloid leukemias. MPNs are: Chronic myelogenous leukemia, Chronic neutrophilic leukemia, Polycythemia vera (PV), Primary myelofibrosis (PMF), Essential thrombocythemia (ET), Chronic eosinophilic leukemia (not otherwise specified), Mastocytosis (Vardinan et al. 2009).
In myelodisplastic syndromes (MDS) the cells of bone marrow do not mature into healthy blood cells. MDS are: Refractory anemia (RA), Refractory anemia with ringed sideroblasts (RARS), Refractory cytopenia with multilineage dysplasia (RCMD), Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), Refractory anemia with excess blasts (RAEB), Myelodysplastic syndrome, unclassified (MDS-U), MDS associated with isolated del(5q), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) (Germing et al. 2013).
Acute myelogenous/myeloid leukemia (AML) originates from myeloid stem cells or myeloid blasts halted in an immature state during haematopoiesis. AML represents a group of heterogeneous forms of myeloid malignancies with diverse genetic abnormalities and different stages of myeloid differentiation. AML is characterized by rapid growth and accumulation of abnormal white blood cells in the bone marrow. AML interfers with the production of normal blood cells. The prototype cells used in our studies are the human cell line, HL-60 which belongs to a sub-type of AML, namely acute promyelocytic leukemia (APL).
Current treatment of myeloproliferative, myelodysplastic diseases or myeloid leukemias are diverse. There is no available curative treatment for any type of MPNs. The aim of therapies in MPNs are to limit the severity of symptoms to avoid thrombohemorrhagic complications, limit anemia and splenomegaly. Low dose aspirin is effective in PV and ET. Tyrosine kinase inhibitors (e.g. imatinib) have improved the prognosis of CML patients (Moen et al. 2007; Tefferi and Pardanani 2015).
The aims of the therapies in the case of MDS are also to diminish the symptoms, improve the quality of life and decrease progression to AML. Allogeneic stem cell (bone marrow) transplantation can be considered under the age of 40 in more severely affected patients. Supporting cares are blood transfusion and the administration of erythropoietin. Chemotherapy for MDSs are performed by the administration of 5-azacytidin, decitabine, lenalidomide (Gangat et al. 2016).
The treatment of AML mostly relies on chemotherapy. Haematopoietic transplantation is suggested mostly in youngers when chemotherapy fails. The aim of the first line treatment called induction phase therapy is complete remission. The second phase is called consolidation therapy to remove any residual disease. During induction therapy cytarabine and anthracycline are given except subtype M3. The acute promyelocytic leukemia (APL, the subtype M3) is treated mainly by all-trans retinoic acid (ATRA). Consolidation chemotherapy eliminates residual malignant cells by a patient-tailored protocol (De Kouchkovsky and Abdul-Hay 2016).
Another pathologic condition of myeloid expansion is the “emergency” granulo-monocytopoiesis in most of the solid malignancies in which, an army of immature myeloid cells leave the bone marrow, called monocytic and granulocytic myeloid-derived suppressor cells (MDSCs) (Strauss et al. 2015). In contrast to AML, MDSCs are not malignant cells, but promote angiogenesis and immunosuppression leading to the progression of cancer. Both in AML and in solid malignancies the differentiation of immature myeloid cells is an already established therapeutic concept (Szebeni et al. 2016).
The most common myeloid infiltrate in solid tumors is composed by myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) (Szebeni et al. 2017b). In a human phase 1B clinical study 25-dihydroxyvitamin D3 reduced the number of CD34+ immunosuppressive cells, increased HLA-DR expression, elevated plasma IL-12 and IFN-γ level in the blood of HNSSC patients (Lathers et al. 2004). ATRA dramatically reduced the percentage of immature myeloid suppressive cells in the blood of human metastatic renal cell carcinoma patients and improved antigen specific T-cell response (Mirza et al. 2006). The TLR7/8 agonist imidazoquinoline-like molecule, resiquimod treated MDSCs differentiated to F4/80+ macrophages and CD11c+/MHCII+ (I-Ad+) dendritic cells exerting potent T-cell stimulatory function (Lee et al. 2014).
MDSCs promote tumor growth by several mechanisms including their inherent immunosuppressive activity, promotion of neoangiogenesis, mediation of epithelial-mesenchymal transition and altering cancer cell metabolism. The pro-tumoral functions of TAMs and MDSCs are further enhanced by their cross-talk offering a myriad of potential anti-cancer therapeutic targets. Since MDSCs represent immature myeloid cells with inherent immunosuppressive activity differentiation of MDSCs into mature myeloid cells thereby restoration of T-cell immunity would be a promising therapeutic strategy (Wesolowski et al. 2013).
Besides inducing differentiation of promyelocytic cells, differentiation induction of various solid cancer cells can also result in apoptosis and cell death. Therefore, the invented compounds could be used not only for eliminating immature leukemia cells in leukemia, or diminishing tumor-promoting cells in solid tumor microenvironment, but the compounds can also act as cytotoxic agents directly on solid tumor cells.
Treating malignant tumor by inducing cell differentiation has been an attractive approach, but clinical development of differentiation-inducing agents to treat malignan solid tumors has been limited to date. Nerve growth factor, all trans retinoic acid, dimethyl sulfoxide, butyric acid, cAMP, vitamin D3, peroxisome proliferator-activated receptorgamma, hexamethylene-bis-acetamide, 12-0-tetradecanoylphorbol 13-acetate, transforming growth factor-beta, and vesnarinone are known to have a differentiation-inducing capability on solid tumors (Kawamata et al, 2006). Moreover some of the differentiation-inducing agents have been used in the clinics for solid tumor, but the therapeutic potential of the differentiation-inducing agents on solid tumor is not strong when compared with that of conventional chemotherapeutic agents. However, because most of the differentiation-inducing agents can potentiate the effect of conventional chemotherapy or radiation therapy, combination of differentiation-inducing agents with conventional chemotherapeutics or radiation therapy might be used in patients with advanced cancer.
The present invention relates to substituted imidazo[1,2-b]pyrazole carboxamides that are able to induce differentiation and subsequent cell death in cancer cell. These compounds could be useful for treatment alone or in combination with known chemotherapeutic agents.
Due to the high mortality of sepsis there is an unmet high medical need for novel therapies. MDSCs can also be targeted in sepsis based on current publications.
It has been published that myeloid-derived cells emerge in septic patients suppressing antigen-driven T-cell proliferation, TH1/Th2 cytokine production contributing to higher prevalence of nosocomial infections.
(Mathias et al. 2017)
Monocytic MDSCs are accumulated in all septic patients whereas granulocytic MDSCs are increased in gram positive case. (Janols et al. 2014)
It has been published that matured MDSCs loose their inherent immunosuppressive phenotype that could solve the dormant state of the antigen specific immune response in sepsis. (McPeak et al. 2017)
MDSCs are immature myeloid cells like our model cell line Hl-60, so based on our previous results XXX compounds may differentiate MDSC as Hl-60 cells have been differentiated upon treatment.
1) Chemical Part of the Invention
The present invention relates to novel imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives and pharmaceutically acceptable salts thereof, the synthesis thereof, and medicinal and/or pharmaceutical composition comprising these compounds thereof and synthesis thereof,
2) Biological Part of the Invention
Concerning the chemical examples of the synthesys of the novel imidazo[1,2-b]pyrazole carboxamide derivatives almost all compounds are of the general formulas of I and IV except the one example 97, where compounds of general formula I′ and IV′ are disclosed, and the prepared compound is a pyrazole carbothioamide.
Therefore only the numbers of the general formula are indicated in the examples with the meaning: “of general formula (number)”.
Accordingly e.g. “reaction conditions (method A): 63 mg
(0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I”, means:
(0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide of general formula (I).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-11H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 58 mg (1.1 equiv.) benzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification.
White solid; yield: 69% (method A); m.p. 246-248° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.61 (s, 1H), 7.99 (d, J=7.8 Hz, 2H), 7.94 (s, 1H), 7.39 (t, J=7.6 Hz, 2H), 7.26 (t, J=7.4 Hz, 1H), 7.08 (bs, 1H), 6.87 (bs, 1H), 4.04 (bs, 1H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 142.4, 137.1, 130.6, 128.2, 127.1, 126.7, 124.1, 121.8, 94.0, 54.7, 30.1; ESI-MS (m/z): 298.2 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 58 mg (1.1 equiv.) benzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. Pale yellow solid; yield: 51%; m.p. 154-156° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.64 (s, 1H), 7.99 (s, 1H), 7.92 (d, J=7.2 Hz, 2H), 7.43 (t, J=7.7 Hz, 2H), 7.32 (t, J=7.4 Hz, 1H), 1.57 (s, 2H), 1.03 (s, 6H), 0.99 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.3, 142.6, 137.5, 131.0, 128.6, 127.8, 127.6, 125.0, 122.1, 94.4, 59.3, 56.0, 32.1, 31.7, 29.5. ESI-MS (m/z): 354.2 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 58 mg (1.1 equiv.) benzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolation with simple filtration. Gray solid; yield: 46%; m.p. 209-210° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.45 (s, 1H), 7.95 (s, 1H), 7.83 (d, J=7.7 Hz, 2H), 7.41 (t, J=7.8 Hz, 2H), 7.25 (t, J=7.4 Hz, 1H), 7.12 (bs, 1H), 6.82 (bs, 1H), 5.59 (s, 1H), 4.22 (s, 2H), 3.55 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 171.9, 163.8, 143.0, 137.3, 130.3, 128.5, 126.4, 126.0, 124.2, 115.3, 93.9, 51.5, 46.0. ESI-MS (m/z): 314.1 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 60 mg (1.1 equiv.) cyclohexyl isocyanide III and 58 mg (1.1 equiv.) benzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 51%; m.p. 240-241° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.49 (s, 1H), 7.95 (s, 1H), 7.91 (d, J=8.0 Hz, 2H), 7.46-7.35 (m, 2H), 7.28-7.19 (m, 1H), 7.12 (bs, 1H), 6.82 (bs, 1H), 4.53 (bs, 1H), 1.81-1.69 (m, 2H), 1.64-1.55 (m, 2H), 1.50-1.40 (m, 1H), 1.24-1.03 (m, 5H). 13C NMR (126 MHz, DMSO-d6) δ 163.8, 142.8, 137.1, 130.4, 128.4, 126.6, 125.8, 123.5, 119.9, 94.0, 54.2, 33.2, 25.5, 24.3. ESI-MS (m/z): 324.1 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 73 mg (1.1 equiv.) 4-methoxyphenyl isocyanide III and 58 mg (1.1 equiv.) benzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. Gray solid; yield: 48%; m.p. 229-231° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.97 (s, 1H), 7.93 (s, 1H), 7.79 (s, 3H), 7.37 (s, 2H), 7.26 (s, 1H), 6.85 (s, 2H), 6.71 (s, 2H), 6.51 (s, 2H), 3.61 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 152.3, 142.5, 139.5, 137.7, 129.4, 128.5, 127.5, 126.0, 124.9, 117.6, 114.7, 114.3, 94.7, 55.3. ESI-MS (m/z): 348.2 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 66 mg (1.1 equiv.) p-tolylbenzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 66%; m.p. 218-219° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.54 (s, 1H), 7.92 (s, 1H), 7.81 (d, J=7.8 Hz, 2H), 7.20 (d, J=7.7 Hz, 2H), 6.82 (bs, 1H), 3.95 (bs, 1H), 3.49 (bs, 1H), 2.30 (s, 3H), 1.54 (s, 2H), 0.98 (s, 6H), 0.97 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 142.2, 136.9, 136.5, 128.7, 127.8, 127.1, 124.4, 121.2, 93.9, 58.8, 55.5, 31.7, 31.3, 29.1, 20.9. ESI-MS (m/z): 368.3 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 75 mg (1.1 equiv.) p-methoxybenzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. Pale yellow solid; yield: 85%; m.p. 124-125° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.43 (s, 1H), 7.91 (s, 1H), 7.86 (d, J=8.3 Hz, 2H), 7.00 (d, J=8.3 Hz, 2H), 6.91-6.74 (bs, 2H), 3.87 (s, 1H), 3.81 (s, 3H), 1.58 (s, 2H), 1.03 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.4, 159.0, 142.5, 137.3, 129.1, 124.8, 123.6, 121.2, 114.1, 94.4, 59.1, 56.1, 55.7, 32.1, 31.8, 29.6. ESI-MS (m/z): 384.3 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 107 mg (1.1 equiv.) disubstituted benzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 50%; m.p. 190-191° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.65 (s, 1H), 7.95 (s, 1H), 7.68 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.34-6.97 (m, 1H), 7.09 (d, J=8.3 Hz, 1H), 6.76 (s, 1H), 4.08 (s, 1H), 3.84 (s, 3H), 2.24 (s, 3H), 1.57 (s, 2H), 1.03 (s, 6H), 0.96 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 168.5, 164.0, 150.5, 142.1, 138.3, 137.3, 129.4, 123.8, 122.5, 121.6, 119.5, 111.7, 94.0, 58.7, 56.0, 55.6, 31.6, 31.3, 29.1, 20.4. ESI-MS (m/z): 442.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 108 mg (1.1 equiv.) 2,4,6-trimethoxybenzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolation with simple filtration and washing with EtOH. Yellow solid; yield: 74%; m.p. 226-227° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.90 (s, 1H), 7.87 (s, 11H), 6.91 (s, 1H), 6.71 (s, 11H), 6.28 (s, 2H), 4.68 (t, J=7.1 Hz, 1H), 3.82 (s, 5H), 3.71 (s, 6H), 3.45 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 171.4, 163.9, 161.8, 159.6, 142.1, 136.5, 124.9, 105.8, 99.3, 93.4, 90.7, 55.7, 55.4, 51.3, 45.9. ESI-MS (m/z): 404.1 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 68 mg (1.1 equiv.) 4-fluorobenzaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. Pale yellow solid; yield: 69%; m.p. 229-230° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.66 (s, 1H), 8.08-7.78 (m, 3H), 7.23 (t, J=8.7 Hz, 2H), 6.84 (bs, 2H), 3.97 (s, 1H), 1.52 (s, 2H), 0.98 (s, 6H), 0.95 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 161.3 (d, J=244.7 Hz), 142.1, 137.2, 129.5 (d, J=8.1 Hz), 127.2, 123.6, 121.4, 115.0 (d, J=21.4 Hz), 94.0, 58.7, 55.5, 31.6, 31.3, 29.0. ESI-MS (m/z): 372.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 68 mg (1.1 equiv.) 4-fluorobenzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolation with simple filtration and washing with EtOH. White solid; yield: 53%; m.p. 229-230° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.49 (s, 1H), 7.95 (s, 1H), 7.88 (dd, J=8.6, 5.3 Hz, 2H), 7.25 (t, J=8.7 Hz, 2H), 7.11 (bs, 1H), 6.79 (bs, 1H), 5.55 (t, J=6.2 Hz, 1H), 4.19 (d, J=6.2 Hz, 2H), 3.55 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 171.9, 163.8, 160.9 (d, J=244.5 Hz), 142.8, 137.3, 128.3 (d, J=5.0 Hz), 126.8, 123.8, 115.3 (d, J=21.3 Hz), 115.1, 93.9, 51.5, 46.0. ESI-MS (m/z): 332.1 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 96 mg (1.1 equiv.) 4-trifluoromethylbenzaldehide II in 1 mL water/ethanol mixture (1:1), stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 69%; m.p. 192-193° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.78 (s, 1H), 8.19 (d, J=8.2 Hz, 2H), 8.01 (s, 1H), 7.77 (d, J=8.2 Hz, 2H), 1.60 (s, 2H), 1.06 (s, 6H), 0.99 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.3, 143.0, 138.3, 135.2, 128.0, 127.7 (q, J=32.0 Hz), 125.4 (q, J=3.5 Hz), 124.8 (q, J=271.7 Hz), 123.4, 94.5, 59.5, 56.0, 32.0, 31.7, 29.5. ESI-MS (m/z): 422.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 77 mg (1.1 equiv.) 3,4-difluorobenzaldehide II in 1 mL water/ethanol mixture (1:1), stirring at room temperature for six hours. Isolation by simple filtration. White solid; yield: 80%; m.p. 256-258° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.73 (s, 1H), 8.12 (ddd, J=13.0, 7.8, 2.2 Hz, 1H), 7.97 (s, 1H), 7.92-7.84 (m, 1H), 7.46 (dt, J=10.7, 8.7 Hz, 1H), 7.13 (bs, 1H), 6.85 (bs, 1H), 4.25 (bs, 1H), 1.05 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 149.2 (dd, J=243.6, 12.7 Hz), 148.3 (dd, J=246.6, 12.4 Hz), 142.3, 137.6, 128.2, 123.6, 122.3, 117.34 (d, J=17.1 Hz), 115.51 (d, J=19.5 Hz), 94.1, 54.8, 30.1. ESI-MS (m/z): 334.4 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 59 mg (1.1 equiv.) 3-pyridine carboxaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 82%; m.p. 226-228° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.82 (s, 1H), 9.11 (s, 1H), 8.46 (s, 1H), 8.27 (d, J=8.1 Hz, 1H), 7.97 (s, 1H), 7.43 (t, J=6.6 Hz, 1H), 7.14 (bs, 1H), 6.80 (bs, 1H), 4.18 (s, 1H), 1.51 (s, 2H), 0.98 (s, 6H), 0.94 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 147.9, 147.6, 142.2, 138.0, 134.6, 126.9, 123.2, 122.4, 121.7, 94.1, 58.7, 55.5, 31.6, 31.3, 29.1. ESI-MS (m/z): 355.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butylisocyanide III and 80 mg (1.1 equiv.) α-methylcinnamaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 65%; m.p. 190-191° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.33 (s, 1H), 7.92 (s, 1H), 7.40-7.34 (m, 4H), 7.28-7.19 (m, 1H), 7.02 (s, 1H), 6.77 (bs, 1H), 4.15 (bs, 1H), 3.40 (bs, 1H), 2.29 (s, 3H), 1.11 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 142.2, 137.2, 136.7, 128.9, 128.5, 128.3, 127.2, 127.0, 126.6, 121.9, 93.8, 54.5, 30.0, 16.7. ESI-MS (m/z): 338.2 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 62 mg (1.1 equiv.) cyclohexylaldehide II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 39%; m.p. 190-192° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.15 (s, 1H), 7.81 (s, 1H), 6.96 (bs, 1H), 6.70 (bs, 11H), 3.75 (s, I H), 2.71 (t, J=12.2 Hz, 11H), 1.79-1.68 (m, 4H), 1.67-1.57 (m, 3H), 1.54 (s, 2H), 1.32-1.19 (m, 3H), 1.12 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.3, 140.8, 136.9, 130.1, 119.3, 93.6, 57.2, 55.1, 33.9, 31.7, 31.5, 31.3, 29.0, 26.4, 25.3. ESI-MS (m/z): 360.3 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 70 mg (1.1 equiv.) octanal II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 44%; m.p. 203-204° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.18 (s, 1H), 7.82 (s, 1H), 7.00 (bs, 1H), 6.69 (bs, 1H), 3.84 (bs, 1H), 1.60 (t, J=7.7 Hz, 2H), 1.32-1.18 (m, 10H), 1.09 (s, 9H), 0.88-0.78 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.4, 140.5, 137.2, 125.5, 120.7, 93.7, 53.6, 31.2, 30.1, 28.8, 28.6, 28.4, 24.2, 22.1, 14.0. ESI-MS (m/z): 320.3 (M+H+).
Reaction conditions (method A): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 60 mg (1.1 equiv.) cyclohexyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Flash chromatography purification with Hexane:Etil-acetate mixture. White solid; yield: 43%; m.p. 148-149° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.67 (s, 1H), 7.79 (s, 1H), 6.99 (bs, 11H), 6.63 (bs, 1H), 3.80 (s, 1H), 3.25 (s, 11H), 1.76-1.57 (m, 4H), 1.49 (s, 1H), 1.33 (s, 9H), 1.10 (s, 4H), 0.94 (s, 1H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 141.8, 135.7, 129.6, 120.6, 93.6, 54.4, 33.3, 31.8, 30.0, 25.6, 24.5. ESI-MS (m/z): 304.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 49%; m.p. 221° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.72 (s, 11H), 7.79 (s, 1H), 7.01 (bs, 1H), 6.71 (bs, 1H), 3.59 (s, 1H), 1.36 (s, 9H), 1.17 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 141.5, 135.9, 132.4, 119.7, 93.5, 52.4, 32.0, 30.7, 30.2. ESI-MS (m/z): 278.2 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 73 mg (1.1 equiv.) 4-methoxyphenyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. Pale yellow solid; yield: 41%; m.p. 260-262° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.19 (s, 1H), 7.79 (s, 1H), 7.22 (s, 1H), 7.11 (bs, 1H), 6.83 (bs, 1H), 6.68 (d, J=8.3 Hz, 2H), 6.38 (d, J=8.4 Hz, 2H), 3.60 (s, 3H), 1.31 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 151.8, 141.6, 141.0, 136.5, 133.9, 115.4, 114.6, 113.7, 94.3, 55.3, 32.0, 29.4. ESI-MS (m/z): 328.2 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 67 mg (1.1 equiv.) 4-fluorophenyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. Gray solid; yield: 54%; m.p. 249-250° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.28 (s, 1H), 7.82 (s, 1H), 7.55 (s, 1H), 7.14 (bs, 1H), 6.91 (t, J=8.6 Hz, 2H), 6.77 (bs, 1H), 6.43 (dd, J=8.5, 4.5 Hz, 2H), 1.32 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 155.3 (d, J=232.6 Hz), 143.6, 141.7, 136.5, 134.2, 115.4 (d, J=22.3 Hz), 114.8, 113.8 (d, J=7.2 Hz), 94.5, 32.0, 29.4. ESI-MS (m/z): 316.1 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 54%; m.p. 155-156° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.73 (s, 1H), 7.81 (s, 1H), 7.01 (s, 1H), 6.72 (s, 11H), 3.42 (s, 1H), 1.66 (s, 2H), 1.38 (s, 9H), 1.21 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 141.5, 135.9, 132.4, 119.5, 93.5, 56.5, 56.1, 32.0, 31.8, 31.4, 30.2, 29.6. ESI-MS (m/z): 334.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 39 mg (1.1 equiv.) cyclopropyl aldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 56%; m.p. 205-207° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.80 (s, 1H), 7.81 (s, 1H), 6.90 (bs, 1H), 6.73 (bs, 1H), 3.60 (bs, 1H, overlap with water), 2.00-1.92 (m, 1H), 1.59 (s, 2H), 1.14 (s, 6H), 1.02 (s, 9H), 0.91-0.87 (m, 2H), 0.85-0.80 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 164.1, 141.1, 136.2, 126.1, 121.5, 93.8, 58.1, 55.3, 31.8, 31.4, 29.2, 7.1, 6.6. ESI-MS (m/z): 318.2 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 32 mg (1.1 equiv.) propionaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 51%; m.p. 207-209° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.19 (s, 1H), 7.82 (s, 1H), 7.01 (bs, 1H), 6.65 (bs, 1H), 3.68 (s, 1H), 2.55-2.50 (m, 2H), 1.54 (s, 2H), 1.20-1.13 (m, 3H), 1.10 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.4, 140.5, 137.3, 126.6, 120.1, 93.6, 57.4, 55.2, 31.8, 31.4, 29.1, 17.7, 13.8. ESI-MS (m/z): 306.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 40 mg (1.1 equiv.) isopropyl aldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 42%; m.p. 132-134° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.17 (s, 1H), 7.82 (s, 1H), 6.97 (bs, 1H), 6.70 (bs, 1H), 3.70 (bs, 1H), 3.12-3.02 (in, 1H), 1.55 (s, 2H), 1.22 (d, J=7.1 Hz, 6H), 1.12 (s, 6H), 1.00 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.3, 140.8, 137.2, 130.7, 119.0, 93.7, 57.2, 55.2, 31.8, 31.4, 29.1, 24.0, 21.8. ESI-MS (m/z): 320.4 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 62 mg (1.1 equiv.) 2,2-dimethylpent-4-enal II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 45%; m.p. 161-163° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.72 (s, 1H), 7.81 (s, 1H), 7.04 (s, 1H), 6.72 (s, 1H), 5.67-5.55 (m, 1H), 5.05-4.89 (m, 2H), 3.43 (s, 1H), 1.65 (s. 2H), 1.35 (s, 6H), 1.22 (s, 6H), 0.99 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.0, 141.5, 136.0, 135.5, 131.0, 120.5, 117.3, 93.5, 56.4, 56.1, 46.2, 35.2, 31.8, 31.4, 29.6, 27.7. ESI-MS (m/z): 360.3 (M+H+).
Reaction conditions (method B): 63 mg (0.5 mmol) 5-amino-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 84 mg (1.1 equiv.) 4-ethyl-4-formylhexanenitrile II in 1 ML water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 35%; m.p. 184-186° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 7.83 (s, 1H), 7.05 (bs, 1H), 6.74 (bs, 1H), 3.56 (d, J=2.1 Hz, 1H), 2.32-2.22 (m, 2H), 2.19-2.13 (m, 2H), 1.76 (q, J=7.2 Hz, 4H), 1.66 (s, 2H), 1.27 (s, 6H), 1.00 (s, 9H), 0.68 (t, J=6.9 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 141.7, 136.2, 128.2, 122.8, 121.0, 93.7, 56.2, 56.1, 42.4, 31.8, 31.4, 29.6, 26.6, 11.5, 7.9. ESI-MS (m/z): 401.4 (M+H+).
Reaction conditions (method B): 70 mg (0.5 mmol) 5-amino-N-methyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 1 mL water/ethanol mixture, stirring at room temperature for 30 minutes. Isolation by simple filtration. White solid; yield: 31%; m.p. 173-174° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.75 (s, 1H), 7.81 (s, 1H), 7.46 (d, J=6.2 Hz, 1H), 3.46 (s, 1H), 2.75 (d, J=4.4 Hz, 3H), 1.68 (s, 2H), 1.41 (s, 9H), 1.23 (s, 6H), 1.03 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.2, 141.1, 136.2, 132.8, 119.9, 94.0, 56.9, 56.5, 32.5, 32.2, 31.9, 30.7, 30.1, 25.8. ESI-MS (m/z): 348.4 (M+H+).
Reaction conditions (method A): 90 mg (0.5 mmol) 5-amino-N-butyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 43%; m.p. 147-148° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.73 (s, 1H), 7.84 (s, 1H), 7.52 (t, J=5.9 Hz, 1H), 3.45 (s, 1H), 3.22 (q, J=6.7 Hz, 2H), 1.68 (s, 2H), 1.48 (q, J=7.2 Hz, 2H), 1.41 (s, 9H), 1.33 (q, J=7.5 Hz, 2H), 1.23 (s, 6H), 1.03 (s, 9H), 0.91 (t, J=7.3 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 162.7, 140.8, 136.5, 132.9, 119.9, 94.2, 56.9, 56.5, 38.4, 32.5, 32.2, 31.9, 30.7, 30.1, 20.1, 14.3. ESI-MS (m/z): 390.3 (M+H+).
Reaction conditions (method A): 91 mg (0.5 mmol) 5-amino-N-(tert-butyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 66%; m.p. 177-178° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.74 (s, 1H), 7.93 (s, 1H), 6.94 (s, 1H), 3.43 (s, 1H), 1.67 (s, 2H), 1.40 (s, 9H), 1.38 (s, 9H), 1.23 (s, 6H), 1.03 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 13C NMR (126 MHz, DMSO) δ 163.1, 140.2, 137.6, 132.9, 119.7, 95.1, 57.0, 56.5, 50.6, 32.5, 32.2, 31.8, 30.7, 30.1, 29.7. ESI-MS (m/z): 390.4 (M+H+).
Reaction conditions (method A): 83 mg (0.5 mmol) 5-amino-N-cyclopropyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 57%; m.p. 161° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.76 (s, 1H), 7.82 (s, 1H), 7.64-7.55 (m, 1H), 2.75-2.68 (m, 1H), 1.67 (s, 2H), 1.40 (s, 9H), 1.23 (s, 6H), 1.03 (s, 9H), 0.69-0.64 (m, 2H), 0.52-0.48 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.9, 140.9, 136.6, 132.9, 119.9, 94.0, 56.9, 56.5, 32.5, 32.2, 31.9, 30.7, 30.1, 22.7, 6.5. ESI-MS (m/z): 374.4 (M+H+).
Reaction conditions (method A): 97 mg (0.5 mmol) 5-amino-N-cyclopentyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 38%; m.p. 182-183° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.75 (s, 1H), 7.90 (s, 1H), 7.40 (s, 1H), 4.19 (s, 1H), 3.44 (s, 1H), 1.89 (s, 2H), 1.69 (s, 4H), 1.51 (s, 4H), 1.41 (s, 9H), 1.24 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 164.3, 140.5, 136.6, 133.2, 120.0, 93.4, 57.2, 56.5, 50.9, 32.2, 31.9, 31.2, 31.0, 29.4, 29.1, 23.5. ESI-MS (m/z): 402.4 (M+H+).
Reaction conditions (method A): 108 mg (0.5 mmol) 5-amino-N-benzyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 49%; m.p. 118-119° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.14 (t, J=6.1 Hz, 1H), 7.91 (s, 1H), 7.35-7.30 (m, 4H), 7.28-7.20 (m, 1H), 4.46 (d, J=6.0 Hz, 2H), 3.48 (s, 1H), 1.69 (s, 2H), 1.41 (s, 9H), 1.24 (s, 6H), 1.03 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 162.8, 141.1, 141.1, 136.6, 132.9, 128.7, 127.6, 127.0, 120.0, 93.9, 56.9, 56.5, 42.2, 32.5, 32.3, 31.9, 30.7, 30.1. ESI-MS (m/z): 424.3 (M+H+).
Reaction conditions (method A): 101 mg (0.5 mmol) 5-amino-N-phenyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 55%; m.p. 147° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.42 (s, 1H), 8.13 (s, 11H), 7.73 (d, J=7.2 Hz, 2H), 7.31 (t, J=7.9 Hz, 2H), 7.02 (t, J=7.4 Hz, 1H), 3.52 (s, 1H), 1.70 (s, 21H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.5, 140.8, 140.4, 137.5, 133.3, 129.0, 122.9, 120.1, 120.1, 94.4, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 410.3 (M+H+).
Reaction conditions (method A): 102 mg (0.5 mmol) 5-amino-N-(pyridin-2-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 29%; m.p. 144-145° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.17 (s, 1H), 10.05 (s, 1H), 8.33 (d, J=4.8 Hz, 1H), 8.29 (s, 1H), 8.22 (d, J=8.5 Hz, 1H), 7.76 (t, J=8.0 Hz, 1H), 7.07 (t, J=6.1 Hz, 1H), 3.53 (s, 1H), 1.69 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 153.5, 148.1, 141.9, 138.2, 137.2, 133.2, 120.2, 119.0, 114.3, 94.0, 57.0, 56.5, 32.6, 32.3, 31.9, 30.7, 30.1. ESI-MS (m/z): 411.3 (M+H+).
Reaction conditions (method A): 102 mg (0.5 mmol) 5-amino-N-(pyridin-3-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethyl butylisocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 31%; m.p. 186-187° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.14 (s, 1H), 9.63 (s, 1H), 8.93 (d, J=2.4 Hz, 1H), 8.23 (dd, J=4.7, 1.5 Hz, 1H), 8.15 (s, 1H), 8.13-8.10 (m, 1H), 7.35 (dd, J=8.3, 4.7 Hz, 1H), 3.54 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) S 161.6, 143.8, 141.7, 140.9, 137.5, 137.1, 133.4, 126.8, 123.9, 120.2, 94.0, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 411.3 (M+H+).
Reaction conditions (method A): 102 mg (0.5 mmol) 5-amino-N-(pyridin-4-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Pale yellow solid; yield: 23%; m.p. 185-186° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.24 (s, 1H), 9.80 (s, 1H), 8.40 (d, J=5.5 Hz, 2H), 8.17 (s, 1H), 7.73 (d, J=5.4 Hz, 2H), 3.56 (s, 1H), 1.69 (s, 2H), 1.42 (s, 9H), 1.24 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.9, 150.5, 147.2, 141.0, 137.6, 133.5, 120.2, 113.7, 94.1, 57.0, 56.4, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 411.3 (M+H+).
Reaction conditions (method A): 105 mg (0.5 mmol) 5-amino-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 44%; m.p. 125-127° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.86 (s, 1H), 11.35 (s, 1H), 8.31 (s, 1H), 7.48 (d, J=3.6 Hz, 1H), 7.14 (d, J=3.5 Hz, 1H), 3.55 (s, 1H), 1.69 (s, 2H), 1.42 (s, 9H), 1.24 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 160.1, 159.5, 141.8, 137.8, 137.3, 133.4, 120.4, 113.1, 92.5, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 417.3 (M+H+).
Reaction conditions (method A): 108 mg (0.5 mmol) 5-amino-N-(isoxazol-3-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Gray solid; yield: 40%; m.p. 185-186° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.21 (s, 1H), 10.66 (s, 1H), 8.77 (d, J=1.8 Hz, 1H), 8.23 (s, 1H), 7.05 (d, J=1.7 Hz, 1H), 3.53 (s, 1H), 1.68 (s, 2H), 1.42 (s, 9H), 1.24 (s, 6H), 1.03 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 160.7, 159.9, 158.9, 141.8, 137.3, 133.3, 120.3, 99.9, 93.4, 57.0, 56.5, 32.5, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 401.3 (M+H+).
Reaction conditions (method A): 105 mg (0.5 mmol) 5-amino-N-(o-tolyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 30%; m.p. 172° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.96 (s, 11H), 8.93 (s, 1H), 8.04 (s, 11H), 7.37 (d, J=7.8 Hz, 1H), 7.26 (d, J=7.4 Hz, 11H), 7.20 (t, J=7.6 Hz, 1H), 7.12 (t, J=7.4 Hz, 1H), 3.53 (s, 1H), 2.26 (s, 3H), 1.71 (s, 2H), 1.42 (s, 9H), 1.26 (s, 6H), 1.05 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.2, 141.5, 137.3, 136.8, 133.8, 133.1, 130.7, 126.8, 126.3, 125.7, 120.1, 94.0, 57.0, 56.5, 32.5, 32.3, 31.9, 30.7, 30.1, 18.6. ESI-MS (m/z): 424.3 (M+H+).
Reaction conditions (method A): 115 mg (0.5 mmol) 5-amino-N-(3,5-dimethylphenyl)-1H-pyrazole-4-carboxamide) I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Gray solid; yield: 51%; m.p. 180-181° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.02 (s, 1H), 9.28 (s, 1H), 8.11 (s, 1H), 7.38 (d, J=1.6 Hz, 2H), 6.67 (s, 1H), 3.51 (s, 1H), 2.25 (s, 6H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 3C NMR (126 MHz, DMSO-d6) δ 161.4, 140.7, 140.2, 137.8, 137.5, 133.2, 124.4, 120.1, 117.9, 94.5, 57.0, 56.5, 32.5, 32.2, 31.9, 30.7, 30.1, 21.6. ESI-MS (m/z): 438.4 (M+H+).
Reaction conditions (method A): 122 mg (0.5 mmol) 5-amino-N-(4-isopropylphenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 49%; m.p. 155-156° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.04 (s, 1H), 9.35 (s, 1H), 8.12 (s, 11H), 7.64 (d, J=8.1 Hz, 2H), 7.18 (d, J=8.2 Hz, 2H), 3.51 (s, 1H), 2.85 (hept, J=7.0 Hz, 111), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.20 (d, J=6.9 Hz, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.3, 142.8, 140.8, 138.1, 137.5, 133.2, 126.7, 120.1, 120.0, 94.4, 57.0, 56.5, 33.3, 32.6, 32.2, 31.9, 30.7, 30.1, 24.5. ESI-MS (m/z): 452.4 (M+H+).
Reaction conditions (method A): 116 mg (0.5 mmol) 5-amino-N-(4-methoxyphenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 59%; m.p. 187-188° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.29 (s, 1H), 8.08 (s, 1H), 7.61 (d, J=8.7 Hz, 2H), 6.90 (d, J=8.6 Hz, 2H), 3.51 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.2, 155.3, 140.8, 137.3, 133.4, 133.2, 121.9, 120.0, 114.1, 94.3, 57.0, 56.5, 55.6, 32.5, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 440.4 (M+H+).
Reaction conditions (method A): 131 mg (0.5 mmol) 5-amino-N-(2,4-dimethoxyphenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Light beige solid; yield: 39%; m.p. 127° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.95 (s, 1H), 8.51 (s, 1H), 8.00 (s, 1H), 7.50 (d, J=8.7 Hz, 1H), 6.64 (s, 1H), 6.52 (d, J=8.8 Hz, 1H), 3.81 (s, 3H), 3.77 (s, 3H), 3.52 (s, 1H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.3, 157.7, 153.5, 141.3, 136.7, 133.0, 126.5, 120.7, 120.1, 104.5, 99.2, 94.1, 56.9, 56.5, 56.1, 55.8, 32.5, 32.3, 31.9, 30.7, 30.1. ESI-MS (m/z): 470.4 (M+H).
Reaction conditions (method A): 135 mg (0.5 mmol) 5-amino-N-(2-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 34%; m.p. 106° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.01 (s, 1H), 9.11 (s, 1H), 8.02 (s, 1H), 7.77 (d, J=7.9 Hz, 1H), 7.71 (t, J=7.6 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.48 (t, J=7.7 Hz, 1H), 3.54 (s, 1H), 1.71 (s, 2H), 1.42 (s, 9H), 1.26 (s, 6H), 1.05 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.9, 141.5, 136.9, 136.7, 133.3, 133.1, 131.4, 126.9, 126.8 (q, J=4.6 Hz), 126.2 (q, J=29.1 Hz), 124.3 (d, J=273.6 Hz), 120.2, 93.6, 57.0, 56.5, 32.5, 32.3, 31.9, 30.7, 30.1. ESI-MS (m/z): 478.3 (M+H+).
Reaction conditions (method A): 135 mg (0.5 mmol) 5-amino-N-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 54%; m.p. 180° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.15 (s, 1H), 9.78 (s, 1H, 8.34 (s, 1H), 8.16 (s, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.55 (t, J=8.0 Hz, 1H), 7.35 (d, J=7.6 Hz), 3.54 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.7, 141.3, 140.7, 137.7, 133.4, 130.1, 129.7 (q, J=31.3 Hz), 124.8 (q, J=272.3 Hz), 123.2, 120.2, 119.0 (q, J=3.7 Hz), 115.9 (q, J=4.3 Hz), 94.1, 57.0, 56.4, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 478.4 (M+H+).
Reaction conditions (method A): 135 mg (0.5 mmol) 5-amino-N-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 39%; m.p. 155-156° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.17 (s, 1H), 9.78 (s, 1H), 8.17 (s, 1H), 7.97 (d, J=8.5 Hz, 2H), 7.67 (d, J=8.5 Hz, 2H), 3.54 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 144.2, 140.9, 137.6, 133.4, 126.3 (d, J=3.5 Hz), 125.1 (q, J=271.0 Hz), 122.7 (q, J=31.7 Hz), 120.2, 119.6, 94.2, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 478.4 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(2-fluorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 39%; m.p. 153-154° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.91 (s, 1H), 9.08 (s, 1H), 8.09 (s, 1H), 7.74-7.65 (m, 1H), 7.29-7.22 (m, 1H), 7.22-7.16 (m, 2H), 3.46 (s, 1H), 1.73 (s, 2H), 1.44 (s, 9H), 1.27 (s, 6H), 1.06 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.2, 155.8 (d, J=245.3 Hz), 141.6, 137.1, 133.2, 127.0, 126.9, 126.0 (d, J=7.5 Hz), 124.5 (d, J=3.3 Hz), 120.3, 116.0 (d, J=20.2 Hz), 93.8, 57.1, 56.6, 32.5, 32.2, 31.8, 30.7, 30.1. ESI-MS (m/z): 428.3 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(3-fluorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 47%; m.p. 159° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.13 (s, 1H), 9.62 (s, 1H), 8.14 (s, 1H), 7.78 (dt, J=12.3, 2.4 Hz, 1H), 7.56-7.42 (m, 1H), 7.39-7.26 (m, 1H), 6.83 (td, J=8.4, 2.6 Hz, 1H), 3.53 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.6, 162.6 (d, J=240.2 Hz), 142.3 (d, J=11.2 Hz), 140.8, 137.6, 133.3, 130.5 (d, J=9.7 Hz), 120.1, 115.5, 109.1 (d, J=21.2 Hz), 106.5 (d, J=26.5 Hz), 94.2, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 428.4 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 49%; m.p. 188° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.48 (s, 1H), 8.10 (s, 1H), 7.80-7.67 (m, 2H), 7.15 (t, J=8.9 Hz, 2H), 3.52 (s, 1H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.4, 158.1 (d, J=238.7 Hz), 140.8, 137.4, 136.7, 133.3, 121.8 (d, J=7.9 Hz), 120.1, 115.5 (d, J=22.0 Hz), 94.2, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 428.4 (M+H+).
Reaction conditions (method A): 118 mg (0.5 mmol) 5-amino-N-(4-chlorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 50%; m.p. 188° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.55 (s, 1H), 8.12 (s, 1H), 7.77 (d, J=8.8 Hz, 2H), 7.36 (d, J=8.7 Hz, 2H), 3.52 (s, 1H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.4, 140.8, 139.4, 137.5, 133.3, 128.9, 126.4, 121.5, 120.1, 94.19, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 444.3 and 446.3 (M+H+).
Reaction conditions (method A): 140 mg (0.5 mmol) 5-amino-N-(4-bromophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Pale yellow solid; yield: 42%; m.p. 153-154° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 9.55 (s, 1H), 8.12 (s, 1H), 7.72 (d, J=8.5 Hz, 2H), 7.49 (d, J=8.5 Hz, 2H), 3.53 (s, 1H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.4, 140.8, 139.8, 137.5, 133.3, 131.8, 121.9, 120.1, 114.3, 94.2, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 488.2 and 490.3 (M+H+).
Reaction conditions (method A): 124 mg (0.5 mmol) 5-amino-N-(4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Yellow solid; yield: 38%; m.p. 199° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 1H), 10.06 (s, 1H), 8.24 (d, J=9.2 Hz, 2H), 8.19 (s, 1H), 8.01 (d, J=9.1 Hz, 2H), 3.57 (s, 1H), 1.69 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 147.1, 141.9, 141.2, 137.7, 133.5, 125.2, 120.4, 119.2, 94.1, 57.1, 56.5, 32.6, 32.2, 31.8, 30.7, 30.1. ESI-MS (m/z): 455.3 (M+H+).
Reaction conditions (method A): 113 mg (0.5 mmol) 5-amino-N-(4-cyanophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 48%; m.p. 199° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.20 (s, 1H), 9.85 (s, 1H), 8.16 (s, 1H), 7.94 (d, J=8.8 Hz, 2H), 7.76 (d, J=8.7 Hz, 2H), 3.55 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 144.9, 141.0, 137.6, 133.5, 133.4, 120.2, 119.8, 119.7, 104.2, 94.1, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 435.3 (M+H+).
Reaction conditions (method A): 137 mg (0.5 mmol) ethyl 4-(5-amino-1H-pyrazole-4-carboxamido) benzoate I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 60%; m.p. 127-128° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.17 (s, 1H), 9.78 (s, 1H), 8.17 (s, 1H), 7.97-7.83 (m, 4H), 4.29 (q, J=7.1 Hz, 2H), 3.54 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.32 (t, J=7.1 Hz, 3H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 165.9, 161.6, 145.1, 140.9, 137.6, 133.4, 130.5, 123.6, 120.2, 119.1, 94.3, 60.8, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1, 14.7. ESI-MS (m/z): 482.4 (M+H+).
Reaction conditions (method A): 124 mg (0.5 mmol) 5-amino-N-(4-(methylthio)phenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 28%; m.p. 169-170° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.06 (s, 1H), 9.44 (s, 1H), 8.11 (s, 1H), 7.70 (d, J=8.3 Hz, 2H), 7.25 (d, J=8.3 Hz, 2H), 3.52 (s, 1H), 2.46 (s, 3H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.4, 140.8, 138.0, 137.5, 133.3, 131.1, 127.7, 120.8, 120.1, 94.3, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1, 16.2. ESI-MS (m/z): 456.3 (M+H+).
Reaction conditions (method A): 123 mg (0.5 mmol) 5-amino-N-(4-(dimethylamino)phenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. Gray solid; yield: 37%; m.p. 176-177° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.96 (s, 1H), 9.16 (s, 1H), 8.06 (s, 1H), 7.51 (d, J=8.6 Hz, 2H), 6.72 (d, J=8.5 Hz, 2H), 3.50 (s, 1H), 3.35 (s, 6H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.1, 147.2, 140.8, 137.2, 133.1, 130.1, 121.9, 120.0, 113.2, 94.5, 57.0, 56.5, 41.1, 32.5, 32.3, 31.9, 30.7, 30.1. APCI-MS (m/z): 453.3 (M+H+).
Reaction conditions (method A): 119 mg (0.5 mmol) 5-amino-N-(2,4-difluorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 45%; m.p. 174° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.03 (s, 1H), 9.22 (s, 1H), 8.08 (s, 1H), 7.62 (td, J=8.9, 6.2 Hz, 1H), 7.33 (ddd, J=10.6, 9.1, 2.9 Hz, 1H), 7.18-7.03 (m, 1H), 3.54 (s, 1H), 1.70 (s, 2H), 1.42 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.2, 159.4 (dd, J=243.6, 11.5 Hz), 156.2 (dd, J=248.5, 12.5 Hz), 141.5, 137.0, 133.2, 128.47 (dd, J=9.6, 3.0 Hz), 123.28 (dd, J=12.1, 3.5 Hz), 120.2, 111.42 (dd, J=21.7, 3.3 Hz), 104.6 (dd, J=26.1, 24.9 Hz), 93.5, 57.0, 56.5, 32.5, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 446.3 (M+H+).
Reaction conditions (method A): 119 mg (0.5 mmol) 5-amino-N-(3,4-difluorophenyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL MeCN, stirring at room temperature for six hours. Purification on column chromatography is necessary with Hexane:EtOAc eluent. White solid; yield: 34%; m.p. 162-164° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.64 (s, 1H), 8.11 (s, 1H), 7.95 (ddd, J=13.8, 7.6, 2.4 Hz, 1H), 7.47-7.33 (m, 2H), 3.53 (s, 1H), 1.69 (s, 2H), 1.42 (s, 9H), 1.24 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.5, 149.31 (dd, J=242.0, 13.0 Hz), 145.16 (dd, J=240.2, 12.7 Hz), 140.8, 137.58 (dd, J=9.3, 2.5 Hz), 137.5, 133.3, 120.1, 117.61 (d, J=17.6 Hz), 115.93 (dd, J=5.0, 3.1 Hz), 108.68 (d, J=21.9 Hz), 94.0, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 446.3 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold THF. Yield: 48%. C20H26FN5O1; 1H-NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 9.45 (s, 1H), 8.08 (s, 1H), 7.70 (dd, J=7.9, 5.2 Hz, 2H), 7.12 (t, J=8.6 Hz, 2H), 3.65 (s, 1H), 1.41 (d, J=16.9 Hz, 10H), 1.19 (s, 10H). ESI-MS (m/z): 372.2 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 59 mg (1.1 equiv.) cyclohexyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold THF. Yield: 53%; C22H28FN5O; 1H-NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 9.41 (s, 1H), 8.08 (s, 1H), 7.66 (dd, J=7.9, 5.2 Hz, 2H), 7.15 (t, J=8.6 Hz, 2H), 4.56 (s, 1H), 1.21-1.88 (m, 10H), 1.19 (s, 10H). ESI-MS (m/z): 398.2 v (M+H+).
Reaction conditions (method A): 117 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-3-methyl-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold THF. Yield: 39%; C21H28FN5O; 1H NMR (500 MHz, DMSO) δ 10.66 (s, 1H), 8.79 (s, 1H), 7.60 (dd, J=8.7, 5.1 Hz, 2H), 7.13 (t, J=8.8 Hz, 2H), 2.41 (s, 3H), 1.71 (s, 2H), 1.40 (s, 9H), 1.03 (s, 9H). ESI-MS (m/z): 386.2 (M+H+)).
Reaction conditions (method A): 135 mg (0.5 mmol) 5-amino-N-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold THF. Yield: 49%; C21H26F3N5O; ESI-MS (m/z): 422.2 (M+H+).
Reaction conditions (method A): 135 mg (0.5 mmol) 5-amino-N-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold THF. Yield: 59%. C21H26F3N5O, ESI-MS (m/z): 422.2 (M+H+).
Reaction conditions (method A): 152 mg (0.5 mmol) 5-amino-N-(4-chloro-3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold MeCN. Yield: 55%. C21H25ClF3N5O, ESI-MS (m/z): 456.2 (M+H+).
Reaction conditions (method A): 110 mg (0.5 mmol) 5-amino-N-(5-fluoropyridin-2-yl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL THF, stirring at room temperature for six hours. Isolation by simple filtration and washing with cold MeCN. Yield: 42%. C19H25FN6O; 1H NMR (500 MHz, CDCl3) δ 8.86 (s, 1H), 8.30 (dd, J=9.1, 4.0 Hz, 1H), 8.13 (d, J=2.6 Hz, 2H), 7.85 (s, 1H), 7.44 (m, 1H), 1.44 (s, 9H), 1.30 (s, 9H). ESI-MS (m/z): 373.2 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 96 mg (1.1 equiv.) 4-trifluoromethyl benzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 32% C22H17F4N5O3, ESI-MS (m/z): 476.1 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 106 mg (1.1 equiv.) 3-fluoro-4-trifluoromethyl benzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 44%; C22H16F5N5O3, ESI-MS (m/z): 494.1 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 133 mg (1.1 equiv.) 2,4-bis-trifluoromethyl benzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 41%; C23H16F7N5O3; ESI-MS (m/z): 544.1 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 133 mg (1.1 equiv.) 3,5-bis-trifluoromethyl benzaldehide II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 39%; C23H16F7N5O3; ESI-MS (m/z): 544.1 (M+H+).
Reaction conditions (method B): 117 mg (0.5 mmol) 5-amino-N-(4-fluorobenzyl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. White solid; yield: 33%; m.p. 163-164° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.82 (s, 1H), 8.16 (t, J=6.1 Hz, 1H), 7.90 (s, 1H), 7.46-7.25 (m, 2H), 7.21-7.01 (m, 2H), 4.43 (d, J=6.0 Hz, 2H), 3.48 (s, 1H), 1.68 (s, 2H), 1.40 (s, 9H), 1.24 (s, 6H), 1.03 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 162.8, 161.5 (d, J=241.7 Hz), 141.0, 137.3, 136.6, 132.9, 129.5 (d, J=8.1 Hz), 120.0, 115.4 (d, J=21.2 Hz), 93.8, 56.9, 56.5, 41.5, 32.5, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 442.4 (M+H+).
Reaction conditions (method B): 111 mg (0.5 mmol) 5-amino-N-(5-fluoropyridin-2-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. White solid; yield: 34%; m.p. 140° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.16 (s, 1H), 10.17 (s, 1H), 8.34 (d, J=3.1 Hz, 11H), 8.28 (s, 1H), 8.25 (dd, J=9.2, 4.2 Hz, 1H), 7.74 (td, J=8.8, 3.1 Hz, 1H), 3.53 (s, 1H), 1.69 (s, 2H), 1.43 (s, 9H), 1.24 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.4, 155.7 (d, J=247.1 Hz), 150.0, 141.9, 137.2, 135.3 (d, J=24.7 Hz), 133.2, 125.5 (d, J=19.4 Hz), 120.2, 115.4 (d, J=4.0 Hz), 93.8, 57.0, 56.5, 32.6, 32.2, 31.9, 30.7, 30.1. ESI-MS (m/z): 429.2 (M+H+).
Reaction conditions (method B): 111 mg (0.5 mmol) 5-amino-N-(5-fluoropyridin-3-yl)-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. White solid; yield: 25%; m.p. 177-178° C.; 1H NMR (500 MHz, DMSO-d6) δ 11.15 (s, 1H), 9.72 (s, 1H), 8.58 (s, 1H), 8.29-8.19 (m, 1H), 8.12 (s, 1H), 7.17 (dd, J=9.0, 3.0 Hz, 1H), 3.54 (s, 1H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.48, 158.64 (d, J=231.2 Hz), 140.91, 138.29 (d, J=15.4 Hz), 137.43, 135.37, 133.37, 120.17, 109.53 (d, J=39.4 Hz), 93.77, 56.99, 56.46, 32.57, 32.23, 31.86, 30.69, 30.10. ESI-MS (m/z): 429.2 (M+H+).
Reaction conditions (method B): 117 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-3-methyl-1H-pyrazole-4-carboxamide I; 77 mg (1.1 equiv.) 1,1,3,3-tetramethylbutyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. White solid; yield: 52%; m.p. 179° C.; 1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.82 (s, 1H), 7.63 (dd, J=8.9, 5.1 Hz, 2H), 7.16 (t, J=8.7 Hz, 2H), 3.49 (s, 1H), 2.44 (s, 3H), 1.73 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.05 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 161.9, 158.4 (d, J=239.0 Hz), 151.9, 136.3, 136.3, 131.8, 123.3 (d, J=7.5 Hz), 120.0, 115.3 (d, J=22.0 Hz), 91.4, 56.9, 56.5, 32.4, 32.2, 31.9, 30.8, 30.1, 15.7. ESI-MS (m/z): 442.3 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 54 mg (1.1 equiv.) methyl 2-isocyanoacetate III and 105 mg (1.1 equiv.) 4-(trifluoromethoxy)benzaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 31%; C22H17F4N5O4; ESI-MS (m/z): 492.1 (M+H+).
Reaction conditions (method B): 110 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 39 mg (1.1 equiv.) cyclopropyl aldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 28%; C19H22FN5O; ESI-MS (m/z): 356.1 (M+H+).
Reaction conditions (method B): 140 mg (0.5 mmol) 5-amino-N-(4-bromophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde U1 in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 32%; C20H26BrN5O; ESI-MS (m/z): 432.1 (M+H+).
Reaction conditions (method B): 124 mg (0.5 mmol) 5-amino-N-(4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 38%; C20H26N6O3; 1H NMR (500 MHz, DMSO) δ 11.23 (s, 1H), 10.03 (s, 1H), 8.22 (d, J=9.6 Hz, 2H), 8.16 (s, 1H), 7.97 (d, J=9.6 Hz, 2H), 1.42 (s, 9H), 1.20 (s, 9H). ESI-MS (m/z): 399.2 (M+H).
Reaction conditions (method B): 124 mg (0.5 mmol) 5-amino-N-(4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 39 mg (1.1 equiv.) cyclopropyl aldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 30%; C19H22N6O3; ESI-MS (m/z): 383.2 (M+H+).
Reaction conditions (method B): 131 mg (0.5 mmol) 5-amino-N-(2-methyl-4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation with simple filtration. Yield: 36%; C21H28N6O3; ESI-MS (m/z): 413.2 (M+H+).
Reaction conditions (method B): 131 mg (0.5 mmol) 5-amino-N-(3-hydroxy-4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Purification on column chromatography was required. Yield: 36%; C20H26N6O4; ESI-MS (m/z): 415.2 (M+H+).
Reaction conditions (method B): 131 mg (0.5 mmol) 5-amino-N-(3-hydroxy-4-nitrophenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) Walborsky-reagent III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Purification on column chromatography was required. Yield: 31%; C24H34N6O4; 1H NMR (500 MHz, DMSO) δ 11.27 (s, 1H), 11.13 (s, 1H), 9.02 (s, 1H), 8.16 (s, 1H), 7.77 (dd, J=8.9, 2.6 Hz, 11H), 7.71 (d, J=2.6 Hz, 1H), 3.57 (s, 1H), 1.70 (s, 2H), 1.50 (s, 2H), 1.42 (s, 9H), 1.24 (s, 5H), 1.04 (s, 8H). ESI-MS (m/z): 471.3 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-aminophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 48% (method A: 56%, flash chromatography); C20H28N6O; 1H NMR (500 MHz, D6MSO) δ 10.89 (s, 1H), 9.00 (s, 1H), 8.12 (s, 1H), 8.00 (s, 1H), 7.25 (d, J=8.6 Hz, 2H)), 6.55 (d, J=8.6 Hz, 2H), 1.41 (s, 9H), 1.20 (s, 9H). 13C-NMR (125 MHz, D6MSO) δ 160.6, 144.4, 140.5, 136.6, 132.8, 128.9, 122.2, 120.0, 114.1, 94.3, 52.4, 30.8 and 30.1. ESI-MS (m/z): 369.2 (M+H+).
Reaction conditions (method B): 122 mg (0.5 mmol) 5-amino-N-(4-(dimethylamino)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 53%; C22H32N6O; 1H NMR (500 MHz, DMSO) δ 10.93 (s, 1H), 9.13 (s, 1H), 8.04 (s, 1H), 7.49 (s, 2H), 6.70 (s, 2H), 2.84 (s, 6H), 1.40 (s, 9H), 1.20 (s, 9H). ESI-MS (m/z): 397.3 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-aminophenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 36 mg (1.1 equiv.) cyclopropyl aldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation after flash chromatography. Yield: 27%; C19H24N6O; ESI-MS (m/z): 353.3 (M+H+).
Reaction conditions (method B): 117 mg (0.5 mmol) 5-amino-N-(4-amino-3-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 44%; C20H28N6O2; 1H NMR (500 MHz, DMSO) δ 10.98 (s, 1H), 9.66 (s, 1H), 9.02 (s, 1H), 8.04 (s, 1H), 6.90 (d, J=8.4 Hz, 1H), 6.14 (s, 1H), 6.05 (dd, 1H), 4.86 (s, 2H), 3.68 (s, 1H), 1.39 (s, 9H), 1.21 (s, 9H). ESI-MS (m/z): 385.2 (M+H+).
Reaction conditions (method B): 117 mg (0.5 mmol) 5-amino-N-(4-amino-2-methylphenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 39%; C21H30N6O; ESI-MS (m/z): 383.2 (M+H+).
Reaction conditions (method B): 124 mg (0.5 mmol) 5-amino-N-(4-(methylthio)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 45%; C21H29N5OS; ESI-MS (m/z): 400.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-aminophenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) Walborsky isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Isolation by simple filtration. Yield: 53%; C24H36N6O; ESI-MS (m/z): 425.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 45%; C20H27N5O2; ESI-MS (m/z): 370.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) 1,1,3,3-tetrabutyl methyl isocyanide (Walborsky) III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 48%; 1H NMR (500 MHz, DMSO) δ 10.97 (s, 1H), 9.18 (s, 1H), 9.12 (s, 1H), 8.06 (s, 1H), 7.45 (d, J=7.8 Hz, 2H), 6.71 (d, J=7.7 Hz, 2H), 1.70 (s, 2H), 1.42 (s, 9H), 1.22 (s, 6H), 1.01 (s, 9H). 13C-NMR (125 MHz, D6MSO) δ 161.1, 153.4, 140.7, 137.4, 133.0, 131.7, 122.6, 120.3, 115.9, 94.8, 57.1, 56.5, 32.3, 30.7 and 30.1. ESI-MS (m/z): 426.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 59 mg (1.1 equiv.) cyclohexyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 43%; C22H29N5O2; ESI-MS (m/z): 396.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 59 mg (1.1 equiv.) cyclohexyl isocyanide III and 96 mg (1.1 equiv.) 4-trifluoromethyl benzaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 33%; C25H24F3N5O2; ESI-MS (m/z): 484.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(2-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) 1,1,3,3-tetrabutyl methyl isocyanide (Walborsky) III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 49%; 1H NMR (500 MHz, DMSO) δ 11.12 (s, 1H), 10.04 (s, 1H), 9.18 (s, 1H), 8.13 (s, 1H), 7.49 (d, J=7.8 Hz, 1H), 6.92 (ddd, J=40.1, 15.2, 7.7 Hz, 3H), 3.55 (s, 1H), 1.70 (s, 2H), 1.43 (s, 10H), 1.25 (s, 6H), 1.04 (s, 10H). ESI-MS (m/z): 426.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(3-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) 1,1,3,3-tetrabutyl methyl isocyanide (Walborsky) III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. Yield: 51%; C24H35N5O2; 1H NMR (500 MHz, DMSO) δ 11.03 (s, 1H), 9.34-9.25 (m, 2H), 8.12 (s, 1H), 7.04-7.26 (m, 3H), 6.43 (dd, J=7.9, 1.4 Hz, 1H), 3.51 (s, 1H), 1.70 (s, 2H), 1.44 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). ESI-MS (m/z): 426.2 (M+H+).
Reaction conditions (method B): 116 mg (0.5 mmol) 5-amino-N-(4-hydroxy-2-methylphenyl)-1H-pyrazole-4-carboxamide I; 76 mg (1.1 equiv.) 1,1,3,3-tetrabutyl methyl isocyanide (Walborsky) III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. C25H37N5O2, 1H NMR (500 MHz, DMSO) δ 10.87 (s, 1H), 9.22 (s, 1H), 8.75 (s, 1H), 7.97 (s, 1H), 7.03 (d, J=8.4 Hz, 1H), 6.65 (d, J=2.3 Hz, 1H), 6.59 (dd, J=8.4, 2.5 Hz, 1H), 3.51 (s, 1H), 2.13 (s, 3H), 1.70 (s, 2H), 1.43 (s, 9H), 1.25 (s, 6H), 1.04 (s, 9H). ESI-MS (m/z): 440.4 (M+H+).
Reaction conditions (method B): 118 mg (0.5 mmol) 5-amino-N-(4-fluorophenyl)-1H-pyrazole-4-carbothioamide I′; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for half an hour. Isolated by simple filtration. C20H26FN5S; yield: 17% yellow cristal. 1H NMR (500 MHz, DMSO) δ 10.53 (s, 1H), 10.22 (d, J=36.2 Hz, 1H), 8.14 (s, 1H), 7.70-7.56 (m, 2H), 7.22 (t, J=8.6 Hz, 2H), 3.81 (s, 1H), 1.41 (s, 11H), 1.21 (s, 12H). ESI-MS (m/z): 388.5 (M+H+).
Reaction conditions (method B): 137 mg (0.5 mmol) ethyl 4-(5-amino-1H-pyrazole-4-carboxamido)benzoate I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Flash column chromatography. Yield: 35%; C23H31N5O3; 1H NMR (500 MHz, DMSO) δ 11.14 (s, 1H), 9.75 (s, 1H), 8.15 (s, 1H), 7.89 (s, 4H), 4.27 (d, J=5.1 Hz, 2H), 1.40 (s, 9H), 1.30 (s, 3H), 1.20 (s, 9H). ESI-MS (m/z): 426.2 (M+H+).
C30H42N8O3S; 1H NMR (500 MHz, DMSO) δ 11.01 (s, 1H), 9.75 (s, 1H), 9.33 (s, 1H), 8.08 (d, J=14.7 Hz, 1H), 7.58 (d, J=9.5 Hz, 2H), 7.50-7.42 (m, 2H), 6.41 (s, 1H), 6.33 (s, 1H), 4.28 (d, J=5.3 Hz, 2H), 4.13 (s, 2H), 3.11 (s, 2H), 2.88-2.74 (m, 2H), 2.27 (t, J=6.5 Hz, 3H), 1.58 (dd, J=29.8, 23.7 Hz, 6H), 1.41 (s, 9H), 1.19 (s, 9H). ESI-MS (m/z): 595.3 (M+H+).
Reaction conditions (method B): 135 mg (0.5 mmol) 5-amino-N-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxamide I; 46 mg (1.1 equiv.) tert-butyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Flash column chromatography. Yield: 35%; C21H26F3N5O, 1H NMR (500 MHz, DMSO) δ 11.15 (s, 1H), 9.75 (s, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 7.91 (d, J=8.1 Hz, 11H), 7.55 (t, J=8.0 Hz, 1H), 7.37 (dd, J=21.3, 7.9 Hz, 1H), 3.54 (s, 1H), 1.70 (s, 2H), 1.44 (s, 9H), 1.05 (s, 9H). 13C-NMR (125 MHz, D6MSO) δ 161.7, 141.3, 140.9, 137.7, 133.4, 130.0, 123.2, 120.4, 118.9, 115.9, 94.3, 57.0, 56.7, 32.7, 32.2, 32.1, 30.7 and 30.1. ESI-MS (m/z): 422.2 (M+H+).
Reaction conditions (method B): 109 mg (0.5 mmol) 5-amino-N-(4-hydroxyphenyl)-1H-pyrazole-4-carboxamide I; 53 mg (1.1 equiv.) 1-pentyl isocyanide III and 47 mg (1.1 equiv.) pivalaldehyde II in 0.5 mL EtOH/0.5 mL water, stirring at room temperature for an hour. Purification on column chromatography. Yield: 24%; C21H29N5O2; ESI-MS (m/z): 384.2 (M+H+).
In our experiments three different cell lines were used. Cells were purchased from the American Type Culture Collection (ATCC, Manassas, Va., USA). The human breast adenocarcinoma cell line, MCF-7 cells were maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) 10% fetal calf serum (FCS, Gibco) and mouse mammary carcinoma 4T1 and human promyelocytic leukemia, HL-60 cells were maintained in Roswell Park Memorial Institute 1640 medium (RPMI-1640) 10% FCS. Media were supplemented with 2 mM GlutaMAX, and 100 U/mL penicillin, 100 μg/mL streptomycin (Life Technologies, Carlsbad, Calif., USA). Cell cultures were maintained at 37° C. in a humidified incubator in an atmosphere of 5% CO2 (Sanyo, Japan).
For viability assays cells were seeded in 96 well plates (MCF7 and 4T1: 6000, HL60: 120.000 cells/well) and incubated overnight. Compounds were dissolved in dimethyl sulfoxide (DMSO). Cells were treated with an increasing concentration of compounds having the general formula (I.) (156 nM-100 μM). Cell viability was determined after 72h incubation. Resazurin reagent (Sigma-Aldrich) was dissolved in PBS (pH 7.4) at 0.15 mg/ml concentration, sterile filtered (0.22 μm, Merck Millipore) and aliquoted at −20° C. Resazurin reagent (Sigma-Aldrich) was added at a final concentration of 25 μg/ml. After 2 hours incubation at 37° C. 5% CO2 fluorescence (530 nm excitation/580 nm emission) was recorded on a multimode microplate reader (Cytofluor4000, PerSeptive Biosytems). Viability was calculated with relation to untreated control cells and blank wells containing media without cells. IC50 values (50% inhibiting concentration) were calculated by GraphPad Prism® 5 (La Jolla, Calif., USA).
The determined IC50 values are listed in Table 1.
It is apparent that the applied compounds exhibited a significant citotoxic effect. HL60 cells were highly susceptible to cell death following treatment with selected compounds.
0.604
0.934
0.935
0.183
0.297
0.628
a)IC50 values in μM. Bold values represent compounds displaying an IC50 <1 μM in HL-60 cell line.
To obtain primary human fibroblasts healthy volunteers (age 18-60 years) were enrolled into the study. The punch biopsies were taken from healthy subjects from the breast area undergoing plastic surgery. Primary fibroblasts were obtained from the skin by enzymatic digestion according to a standard protocol. Skin specimens were first washed in Salsol A solution (Human Rt, Gödöllö, Hungary) supplemented with 2% antibiotic/antimycotic solution (Sigma-Aldrich). Skin samples were then cut into narrow strips and incubated in Dispase solution (Roche Diagnostics, Mannheim, Germany) overnight at 4° C. The epidermis was subsequently separated from the dermis. Fibroblasts were obtained by incubating the dermis in Digestion Mix solution (Collagenase, Hyaluronidase and Deoxyribonuclease) for 2h at 37° C. Cell suspensions were filtered through a 100 μm nylon mesh (BD Falcon, San Jose, Calif., USA) and cells were pelleted by centrifugation. Fibroblasts were grown in low glucose DMEM medium containing 5% FBS, 1% antibiotic/antimycotic (PAA, Pasching, Austria) and 1% L-glutamine solution (PAA). Fibroblasts were cultured at 37° C. and 5% CO2 in humidified conditions. Depending on the cell growth, the medium was changed every 2-4 days and cells were passaged at 80% of confluence.
The human primary fibroblasts (6000 cells/well) and Hl60 cells (20.000 cells/well) were seeded into 96-well plates (Corning Life Sciences) in media. Fibroblasts were cultured overnight before treatment. Effects of compounds described in Example 22, 60 and 83 were examined in concentrations of 1 μM, 250 nM, 62.5 nM, 15.6 nM, 3.9 nM and 0.9 nM in 100 μl after 72 h incubation. Resazurin reagent was prepared and used as described in Example 1.
Viability was calculated with relation to untreated control cells and blank wells containing media without cells. IC50 values (50% inhibiting concentration) were calculated by GraphPad Prism® 5. Results are summarized in
Compounds described in Example 22 (
Human promyelocytic leukemia HL60 Cells (500,000/well) were plated in 24-well tissue culture plates (Corning Life Sciences) in RPMI 10% FCS (Gibco) and were treated with the compounds described in Example 60 and 83 at 40 nM, 200 nM and 1 μM concentrations in 500 μl media. After 24 h incubation time cells with the corresponding supernatants were harvested and centrifuged down (2000 rpm, 5 min).
Pellets were resuspended and fixed in 3.5% PBS buffered formaldehyde (Molar Chemicals) for 10 minutes. Cells were washed with FACS-buffer (2% FCS, (Gibco) in PBS), centrifuged down (2000 rpm, 5 min). Cells were permeabilized in Permeability buffer (1% FCS, 0.1% saponin (Sigma-Aldrich) in PBS pH 7.4) for 5 minutes. Cells were washed with FACS buffer (2% FCS, (Gibco) in PBS), centrifuged (2000 rpm, 5 min). The following primary antibodies were used: Bcl-xl-Alexa 488, (Cell Signaling, cat. numb. 2767S), dilution 1:75, 24 h; pAkt-Alexa Fluor 488, (Ser473), (Cell Signaling, cat. numb, 4071), dilution 1:50, 24 or 72h; After incubation for 1h at 4° C. samples were washed two times with FACS buffer. After washing, 300 μl FACS buffer was added for acquisition with the FACSCalibur flow cytometer using the FL1 channel and CellQuest™ software (Becton Dickinson) acquiring 20.000 events. In order to calculate the signal to noise ratio mean fluorescent intensity (MFI) was calculated by the following equation: =POWER(10; (Medianstained−Median unstained, untreated)/Chd), where Chd means 256, the number of channels per decade (Fajka-Boja et al. 2002; Sharrow 2001) in Microsoft Excel. Column charts were created by GraphPad Prism® 5.
HL-60 cells (10×106) were plated in 100 mm tissue culture dishes (Corning Life Sciences) in RPMI 10% FCS. Cells were treated in 10 mL total volume with the compound described in Example 83 24 h after treatment, nucleic acid preparation was done by using the Bioneer RNA purification kit (Bioneer, Viral RNA extraction kit, Daejeon, South Korea) according to an already published protocol (Szebeni et al. 2017a). The quality and quantity of the isolated RNA were measured with NanoDrop1000 Version 3.8.1. (Thermo Fisher Scientific). Reverse transcription from 3 μg of total RNA was performed with the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, Calif., USA) in a total volume of 30 μL according to the manufacturer's protocol. Quantitative-real time PCR was carried out using gene specific primers for CD33 (primer sequences: forward 5′ ctgacctgctctgtgtcctg 3′, reverse 5′ atgagcaccgaggagtgagt 3′) and CD34, (primer sequences: forward 5′ gcgctttgcttgctgagt 3′, reverse 5′ gggtagcagtaccgttgttgt 3′) using Sybr Green detection on a LightCycler Nano instrument (Roche, Hungary). Relative gene expression data was normalized to ACTB (beta actin, primer sequences: forward 5′ attggcaatgagcggttc 3′, reverse 5′ cgtggatgccacaggact 3′) expression.
Experiments detecting CD11b expression by Flow cytometric immunofluorescence were done as described in Example 104 without fixation and permeabilization. Native cell surface staining was done by CD11b-FITC (Immunotools cat number 21389113), with 1:20 dilution 24, 48 and 72 h after treatment.
Results are shown in
Cells (200,000/well) were plated in 24-well tissue culture plates (Corning Life Sciences) and treated with the compounds described in Example 60 and 83 at 40 nM, 200 nM and 1 μM concentrations in 500 μl media. After 24 h cells were harvested with the corresponding supernatant and centrifuged down (2000 rpm, 5 min). Pellets were resuspended in Annexin V binding buffer (0.01 M HEPES, 0.14 M NaCl and 2.5 mM CaCl2). Annexin V-Alexa Fluor® 488 (Life Technologies, 2.5:100) was added to the cells, which were then kept for 15 min in the dark at room temperature. Before the acquisition propidium iodide (10 μg/ml, Sigma-Aldrich) was added in Annexin V binding buffer to dilute Annexin V-Alexa Fluor® 488 5×. Cells (20.000 events) were analyzed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson). The percentage of the FL1 (530/30 nm filter, Annexin V-Alexa Fluor® 488) positive and FL3 (670 nm filter, propidium iodide) negative early apoptotic cells and FL1 positive and FL3 positive late apoptotic cells were determined. The total apoptotic population included both early and late apoptotic cells. Column charts were created by GraphPad Prism® 5. Results are depicted in
Detection of caspase-3 activation by flow cytometric immunofluorescence was done as described in Example 104 with the exception of the used antibodies. Rabbit polyclonal caspase-3 antibody (Cell Signaling, unconjugated, cat numb. 9661S) was added in 1:600 dilution in FACS buffer. After incubation for 1h at 4° C. samples were washed two times with FACS buffer. The secondary antibody for anti-caspase-3, anti-rabbit IgG conjugated with Alexa Fluor® 488 (Thermo Fisher Scientific, A11008) was diluted to 1:600 and incubated with the cells for 30 min at 4° C.
Treatment with compounds described in Example 60 and 83 increased the percentage of active caspase-3 positive cells (
All cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, Va., USA).
GBM2 (human glioblastoma), HeLa (human cervical carcinoma), MIA PaCa-2 (human pancreas carcinoma) and U87MG (human glioblastoma) cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 10% fetal calf serum (FCS, Gibco). A375 (human melanoma), A549 (human lung adenocarcinoma) and HEP3B (human hepatoma) cells were maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) 10% FCS.
HT168 (human melanoma), HT199 (human melanoma), HT29 (human colorectal adenocarcinoma), MOLT4 (human leukemia) and U937 (human lymphoma) cells were maintained in Roswell Park Memorial Institute 1640 medium (RPMI-1640) 10% FCS. SKOV-3 cells were maintained in Dulbecco's Modified Eagle Medium/McCoy's medium (DMEM/McCoy) 10% FCS.
Media were supplemented with 2 mM GlutaMAX, and 100 U/mL penicillin, 100 μg/mL streptomycin (Life Technologies, Carlsbad, Calif., USA). Cell cultures were maintained at 37° C. in a humidified incubator in an atmosphere of 5% CO2 (Sanyo, Japan).
Viability assays were performed as described in Example 102. Calculated IC50 (μM) values are listed in Table 2. The selected compounds exhibited potent cytotoxic activity against all tested cell types.
The effect on mammary carcinoma was studied on BalbC mouse model inoculated subcutaneously into the mammary gland with 4T1 mouse cells (ATCC) (100,000 cells/animal). Two groups were formed from randomly selected mice, with 8 animals in both groups. Group 1: control group, it was only administered a carrier (0.1 mL, 0.9% NaCl solution) intravenously; group 2: group treated with compound 83, it was administered 3 mg/kg of compound 83 in PEG100:Solutol:PBS (1:4:15 vol ratio), intravenously after the tumor reached 300 mm3 (day 16).
The treatments were performed from the sixteenth day, every other day, for a total of 6 occasions. Starting from the 16th day on every day the size of the increasing tumours was determined in the case of each animal, and the group average was represented per group (
The effect on leukaemia was studied on SCID immune-deficient mouse model inoculated intravenously with HL60 human acute myeloid leukaemia cells (ATCC) (1 million cells/animal). Two groups were formed from randomly selected mice, with 9 animals in each group. Group1: control group, it was only administered a carrier (0.1 mL, 0.9% NaCl solution) intravenously; group 2: group treated with compound 60, it was administered 3 mg/kg of compound 60 in PEG100:Solutol:PBS (1:4:15 vol ratio), intravenously.
The treatments were performed from the third day, on five consecutive occasions per week, for 2 weeks, on a total of 10 occasions. As time went on, every day we determined the number of surviving animals and represented it in percentage per group as compared to the total initial number of animals (
The effect on melanoma was studied on SCID immune-deficient mouse model inoculated in the spleen with HTT199 human melanoma cells (ATCC) (1 million cells/animal). Two groups were formed from randomly selected mice, with 10 animals in each group. Group 1: control group, it was only administered a carrier (0.1 mL, 0.9% NaCl solution) intravenously; group 2: group treated with compound 83, it was administered 3 mg/kg of compound 83 in PEG100:Solutol:PBS (1:4:15 vol ratio), intravenously.
The treatments were performed from the third day, on five consecutive occasions per week, for 2 weeks, on a total of 10 occasions. As time went on, every day we determined the number of surviving animals and represented it in percentage per group as compared to the total initial number of animals (
Human primary fibroblasts were obtained from the skin by enzymatic digestion according to a standard protocol. Fibroblasts were grown in low glucose DMEM/F12 medium containing 15% FCS, 1% antibiotic/antimycotic (PAA, Pasching, Austria) and 1% L-glutamine solution (PAA). Fibroblasts were cultured at 37° C. and 5% CO2 in humidified conditions. Depending on the cell growth, the medium was changed every 2-4 days and cells were passaged at 80% of confluence.
Cancer cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, Va., USA). HT29 (human colorectal adenocarcinoma), HL-60 (acute promyelocytic leukemia), THP-1 (acute monocytic leukemia), MOLT-4 (acute T-lymphoblastic leukemia), MV-4-11 (biphenotypic B myelomonocytic leukemia) and K-562 (erythroleukemia) cells were maintained in Roswell Park Memorial Institute 1640 medium (RPMI-1640) with 10% FCS. Media were supplemented with 2 mM GlutaMAX, and 100 U/mL penicillin, 100 μg/mL streptomycin (Life Technologies, Carlsbad, Calif., USA). Cell cultures were maintained at 37° C. in a humidified incubator in an atmosphere of 5% CO2 (Sanyo, Japan).
Viability assays were performed as described in Example 102 with minor modification for cell density and tested concentration range. Applied cell densities: in case of human primary fibroblast 6000, for HT29 4000, for HL-60, MOLT-4, MV-4-11, THP-1, K-562 20000 cells/well. Applied compound concentration range: 10 μM-0.2 nM. Calculated IC50 (nM) values are listed in Table 3. The selected compounds exhibited potent cytotoxic activity against all tested cell types.
Number | Date | Country | Kind |
---|---|---|---|
P1800170 | May 2018 | HU | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/HU2019/000014 | 5/17/2019 | WO | 00 |